Journal
CHEMICAL COMMUNICATIONS
Volume 55, Issue 29, Pages 4254-4257Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c9cc01344j
Keywords
-
Categories
Funding
- National Cancer Institute of the National Institutes of Health [R15CA213103]
Ask authors/readers for more resources
In this study, a folate-targeted pH-sensitive bortezomib conjugate was developed for cancer-specific drug delivery and therapy. The conjugate showed improved cellular uptake, penetration, and anticancer activity compared to free bortezomib, a bortezomib-mannitol derivative, and a PEGylated bortezomib conjugate in folate receptor overexpressing cancer cells and their 3D spheroids.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
